Akari Therapeutics PLC

Company Profile

Akari Therapeutics PLC had its IPO on 2015-09-21 under the ticker symbol AKTX.

The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. Akari Therapeutics PLC has a staff strength of 0 employees.

Stock update

Shares of Akari Therapeutics PLC opened at $0.47 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $0.45 - $0.52, and closed at $0.49.

This is a +4.03% increase from the previous day's closing price.

A total volume of 151,629 shares were traded at the close of the day’s session.

In the last one week, shares of Akari Therapeutics PLC have increased by 0%.

Akari Therapeutics PLC's Key Ratios

Akari Therapeutics PLC has a market cap of $0.029 billion, indicating a price to book ratio of 3.42 and a price to sales ratio of -.

In the last 12-months Akari Therapeutics PLC’s revenue was $0.000 billion with a gross profit of $0.000 billion and an EBITDA of $-0.018 billion. The EBITDA ratio measures Akari Therapeutics PLC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Akari Therapeutics PLC’s operating margin was 0% while its return on assets stood at -141.9% with a return of equity of -365.1%.

In Q2, Akari Therapeutics PLC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Akari Therapeutics PLC’s PE and PEG Ratio

Forward PE

-

Trailing PE

-

PEG

0

Its diluted EPS in the last 12-months stands at $-0.406 per share while it has a forward price to earnings multiple of - and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Akari Therapeutics PLC’s profitability.

Akari Therapeutics PLC stock is trading at a EV to sales ratio of - and a EV to EBITDA ratio of -1.105. Its price to sales ratio in the trailing 12-months stood at -.

Akari Therapeutics PLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$0.000 billion

Total Liabilities

$0.000 billion

Operating Cash Flow

$0.000 billion

Capital Expenditure

$0.000 billion

Dividend Payout Ratio

0%

Akari Therapeutics PLC ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Akari Therapeutics PLC ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Akari Therapeutics PLC’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Akari Therapeutics PLC's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Akari Therapeutics PLC paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price

$0.49

52-Week High

$1.7

52-Week Low

$0.381

Analyst Target Price

$4

Akari Therapeutics PLC stock is currently trading at $0.49 per share. It touched a 52-week high of $1.7 and a 52-week low of $1.7. Analysts tracking the stock have a 12-month average target price of $4.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.